Milad Pourbaghi, PhD
Milad Pourbaghi joined the Sirianni lab group in the fall of 2019. He obtained his PhD in experimental and clinical pharmacology in 2018 from Université d’Angers where he worked on the development of lipid nanocapsules for antiangiogenic treatment of glioblastoma and evaluation of their potential for nose-to-brain drug delivery. His current work in the Sirianni lab focuses on developing new therapeutic tools for targeting the leptomeningeal metastasis of medulloblastoma. He meticulously designs nanoparticles that are employed for efficacious delivery of the polypeptide antibiotic actinomycin for the treatment of medulloblastoma. He is also interested in the development of drug delivery nano-systems for treatment of different types of malignant brain tumors.
Clavreul, Anne & Pourbaghi, Milad & Roger, Emilie & Menei, Philippe. (2019). Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: The story so far. International Journal of Nanomedicine. Volume 14. 2497-2513. 10.2147/IJN.S194858.
Clavreul, Anne & Roger, Emilie & Pourbaghi, Milad & Lemaire, Laurent & Tétaud, Clément & Menei, Philippe. (2018). Development and characterization of sorafenib-loaded lipid nanocapsules for the treatment of glioblastoma. Drug Delivery. 25. 1756-1765. 10.1080/10717544.2018.1507061.
Clavreul, Anne & Pourbaghi, Milad & Roger, Emilie & Lautram, Nolwenn & Montero-Menei, Claudia & Menei, Philippe. (2017). Human mesenchymal stromal cells as cellular drug-delivery vectors for glioblastoma therapy: A good deal?. Journal of Experimental & Clinical Cancer Research. 36. 10.1186/s13046-017-0605-2.